Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 452

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

Capodanno, Davide, Gori, Tommaso, Nef, Holger, Latib, Azeem, Mehilli, Julinda, Lesiak, Maciej, Caramanno, Giuseppe, Naber, Christoph, Di Mario, Carlo, Colombo, Antonio, Capranzano, Piera, Wiebe, Jens, Araszkiewicz, Aleksander, Geraci, Salvatore, Pyxaras, Stelios, Mattesini, Alessio, Naganuma, Toru, Münzel, Thomas, Tamburino, Corrado·2015·EuroIntervention

Abstract

AIMS: Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry. METHODS AND RESULTS: Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1,731 Absorb BVS were implanted at a mean of 12.3±3.4 atm. Technical success was achieved in 99.7% of cases. TLF was recorded in 67 of 1,189 patients at a median of 109 (interquartile range 8-227) days after implantation. The cumulative incidence of TLF was 2.2% at 30 days and 4.4% at six months. The annualised rate of TLF was 10.1%. At six months, the rate of cardiac death was 1.0%, target vessel myocardial infarction was 2.0%, TLR was 2.5%, and target vessel revascularisation was 4.0%. Diabetes mellitus was the only independent predictor of TLF (hazard ratio 2.41, 95% confidence interval: 1.28-4.53; p=0.006). The cumulative incidence of definite/probable scaffold thrombosis was 1.5% at 30 days and 2.1% at six months, with 16 of 23 cases occurring within 30 days. CONCLUSIONS: "Real-world" outcomes of BVS showed acceptable rates of TLF at six months, although the rates of early and midterm scaffold thrombosis, mostly clustered within 30 days, were not negligible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4244/eijy14m07_11

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 452

Metadata

Authors
Capodanno, D., Gori, T., Nef, H., Latib, A., Mehilli, J., Lesiak, M., Caramanno, G., Naber, C., Di Mario, C., Colombo, A., Capranzano, P., Wiebe, J., Araszkiewicz, A., Geraci, S., Pyxaras, S., Mattesini, A., Naganuma, T., Münzel, T., & Tamburino, C.
Venue
EuroIntervention
Published
2015-02
Volume
10
Issue
11
Pages
1144-1153
ISSN
1774-024X (ISSN-L)
OpenAlex
W1979793334
Cited by
452
References
19
FWCI
111.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. https://app.cochat.ai/papers/10.4244/eijy14m07_11
The paper
Capodanno, D., Gori, T., Nef, H., Latib, A., Mehilli, J., Lesiak, M., Caramanno, G., Naber, C., Di Mario, C., Colombo, A., Capranzano, P., Wiebe, J., Araszkiewicz, A., Geraci, S., Pyxaras, S., Mattesini, A., Naganuma, T., Münzel, T., & Tamburino, C. (2015). Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. https://doi.org/10.4244/eijy14m07_11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.